HAZ Stock Overview A healthcare company, provides suite of medical products and solutions in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Haemonetics Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Haemonetics Historical stock prices Current Share Price US$66.00 52 Week High US$89.50 52 Week Low US$64.50 Beta 0.41 1 Month Change -12.58% 3 Month Change 1.54% 1 Year Change -5.71% 3 Year Change 70.98% 5 Year Change -40.00% Change since IPO 216.09%
Recent News & Updates
GVS S.p.A. (BIT:GVS) completed the acquisition of Whole Blood Assets within Blood Center Business from Haemonetics Corporation (NYSE:HAE). Jan 15
Haemonetics Corporation to Report Q3, 2025 Results on Feb 06, 2025 Jan 09
Haemonetics Corporation Announces Retirement of Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, Effective July 11, 2025 Jan 03
Insufficient new directors Dec 30
Investor sentiment improves as stock rises 26% Nov 14
Second quarter 2025 earnings released: EPS: US$0.67 (vs US$0.49 in 2Q 2024) Nov 09 See more updates
GVS S.p.A. (BIT:GVS) completed the acquisition of Whole Blood Assets within Blood Center Business from Haemonetics Corporation (NYSE:HAE). Jan 15
Haemonetics Corporation to Report Q3, 2025 Results on Feb 06, 2025 Jan 09
Haemonetics Corporation Announces Retirement of Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, Effective July 11, 2025 Jan 03
Insufficient new directors Dec 30
Investor sentiment improves as stock rises 26% Nov 14
Second quarter 2025 earnings released: EPS: US$0.67 (vs US$0.49 in 2Q 2024) Nov 09
Haemonetics Corporation to Report Q2, 2025 Results on Nov 07, 2024 Oct 04
Insufficient new directors Sep 01
First quarter 2025 earnings released: EPS: US$0.75 (vs US$0.81 in 1Q 2024) Aug 09
Haemonetics Corporation to Report Q1, 2025 Results on Aug 08, 2024 Jul 09
Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device Jun 19
Haemonetics Corporation, Annual General Meeting, Jul 25, 2024 Jun 10
Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025 May 10
Full year 2024 earnings released: EPS: US$2.32 (vs US$2.27 in FY 2023) May 09
Haemonetics Corporation to Report Q4, 2024 Results on May 09, 2024 Apr 11
Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge Apr 04
Haemonetics Corporation (NYSE:HAE) completed the acquisition of Advanced Cooling Therapy, Inc. Apr 02
Haemonetics Corporation (NYSE:HAE) has entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for $160 million. Mar 05
Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.65 in 3Q 2023) Feb 09
Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024 Feb 08
Haemonetics Corporation to Report Q3, 2024 Results on Feb 08, 2024 Jan 12 Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS). Dec 13
Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS). Dec 12
Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024 Nov 04
Second quarter 2024 earnings released: EPS: US$0.49 (vs US$0.65 in 2Q 2023) Nov 03
Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million. Oct 11
Haemonetics Corporation to Report Q2, 2024 Results on Nov 02, 2023 Oct 06
Haemonetics Corporation Elects Diane M. Bryant to Its Board of Directors Aug 09
First quarter 2024 earnings released: EPS: US$0.81 (vs US$0.39 in 1Q 2023) Aug 09
Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023 Jul 12
Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023 Jul 11
Haemonetics Corporation Receives FDA Clearance for Enhancements to NexSys PCS(R) Plasma Collection System Jun 23
Haemonetics Corporation, Annual General Meeting, Aug 04, 2023 Jun 19
Executive VP & CTO recently sold €179k worth of stock Jun 03
Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024 May 12
Full year 2023 earnings released: EPS: US$2.27 (vs US$0.85 in FY 2022) May 12
Insufficient new directors May 01
Haemonetics Corporation Revises Earnings Guidance for the Year 2023 Feb 08
Third quarter 2023 earnings released: EPS: US$0.65 (vs US$0.46 in 3Q 2022) Feb 08
Investor sentiment improved over the past week Jan 16
Haemonetics Corporation to Report Q3, 2023 Results on Feb 07, 2023 Jan 07
Second quarter 2023 earnings released: EPS: US$0.65 (vs US$0.29 in 2Q 2022) Nov 08
Haemonetics Corporation Updates Revenue Guidance for the Year 2023 Nov 08
Haemonetics Corporation Appoints Maryanne Farris as Principal Accounting Officer Oct 20
Haemonetics Corporation to Report Q2, 2023 Results on Nov 07, 2022 Oct 07
Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center Oct 05
Independent Director recently sold €580k worth of stock Aug 18
First quarter 2023 earnings released: EPS: US$0.39 (vs US$0.087 loss in 1Q 2022) Aug 11 Haemonetics Corporation (NYSE:HAE) announces an Equity Buyback for $300 million worth of its shares.
Haemonetics Corporation Announces Management Changes Aug 10
Haemonetics Corporation to Report Q1, 2023 Results on Aug 10, 2022 Jul 09
Haemonetics Corporation, Annual General Meeting, Aug 05, 2022 Jun 19
CEO, President & Director recently sold €69k worth of stock Jun 17
Haemonetics Corporation Announces Michelle L. Basil, Executive Vice President, General Counsel Has Decided to Transition, Effective October 31, 2022 Jun 17
Haemonetics Corporation Announces Retirement of Dan Goldstein as Vice President, Corporate Controller and Principal Accounting Officer, Effective August 9, 2022 May 26
Insider recently sold €61k worth of stock May 24
Investor sentiment improved over the past week May 19
Haemonetics Corporation Provides Earnings Guidance for the Fiscal Year 2023 May 12
Full year 2022 earnings released: EPS: US$0.85 (vs US$1.57 in FY 2021) May 11
Haemonetics Corporation to Report Q4, 2022 Results on May 10, 2022 Apr 07
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 09
Haemonetics Corporation Reaffirms Earnings Guidance for the Fiscal Year 2022 Feb 09
Second quarter 2022 earnings released: EPS US$0.29 (vs US$0.95 in 2Q 2021) Nov 10
First quarter 2022 earnings released: US$0.087 loss per share (vs US$0.21 profit in 1Q 2021) Aug 12
Independent Chairman Richard Meelia has left the company Aug 10 Haemonetics Corporation(NYSE:HAE) dropped from Russell Midcap Index
Haemonetics Corporation(NYSE:HAE) dropped from Russell 1000 Dynamic Index Jun 27
CEO, President & Director recently sold €59k worth of stock Jun 18
Senior Vice President of Human Resources Jacqueline Scanlan has left the company Jun 15
CEO, President & Director recently sold €123k worth of stock Jun 11
Independent Director recently sold €66k worth of stock May 30
Full year 2021 earnings released: EPS US$1.57 (vs US$1.51 in FY 2020) May 14 Haemonetics Corporation Provides Earnings Guidance for the Fiscal Year 2022
Investor sentiment deteriorated over the past week Apr 21
Investor sentiment improved over the past week Feb 09
New 90-day high: €112 Feb 06
Third quarter 2021 earnings released: EPS US$0.63 (vs US$0.59 in 3Q 2020) Feb 04
Revenue beats expectations Feb 04
Haemonetics Corporation(NYSE:HAE) dropped from Russell 2000 Defensive Index Jan 28
Haemonetics Corporation Welcomes New FDA Guidance on Viscoelastic Testing During COVID-19 Pandemic Jan 24
Haemonetics Corporation (NYSE:HAE) entered into a definitive agreement to acquire Cardiva Medical, Inc. for approximately $570 million. Jan 22
Haemonetics Corporation to Report Q3, 2021 Results on Feb 02, 2021 Jan 06
Haemonetics Corporation Did Not Issue Earnings Guidance for the Full Year of Fiscal 2021 Nov 06
Revenue beats expectations Nov 05
Second quarter 2021 earnings released: EPS US$0.95 Nov 05
Haemonetics Corporation to Report Q2, 2021 Results on Nov 04, 2020 Oct 07
Haemonetics Corporation Receives FDA Clearance for NexSys PCS® With Persona™ Technology Oct 03
Haemonetics Corporation Did Not Provide Earnings Guidance for the Full Year of Fiscal 2021 Aug 17
First quarter earnings released Aug 05
New 90-day low - €63.50 Aug 05
Haemonetics Corporation (NYSE:HAE) acquired enicor GmbH. Jul 30
Haemonetics Corporation to Report Q1, 2021 Results on Aug 04, 2020 Jul 07
Haemonetics Corporation(NYSE:HAE) dropped from Russell 2000 Defensive Index Jul 05 Shareholder Returns HAZ DE Medical Equipment DE Market 7D -1.5% 2.9% 1.9% 1Y -5.7% -1.0% 15.1%
See full shareholder returns
Return vs Market: HAZ underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is HAZ's price volatile compared to industry and market? HAZ volatility HAZ Average Weekly Movement 6.6% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: HAZ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HAZ's weekly volatility (7%) has been stable over the past year.
About the Company Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system.
Show more Haemonetics Corporation Fundamentals Summary How do Haemonetics's earnings and revenue compare to its market cap? HAZ fundamental statistics Market cap €3.35b Earnings (TTM ) €119.44m Revenue (TTM ) €1.31b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HAZ income statement (TTM ) Revenue US$1.36b Cost of Revenue US$607.88m Gross Profit US$753.35m Other Expenses US$629.53m Earnings US$123.81m
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
Feb 06, 2025
Earnings per share (EPS) 2.47 Gross Margin 55.34% Net Profit Margin 9.10% Debt/Equity Ratio 139.6%
How did HAZ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 04:13 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/28 Annual Earnings 2024/03/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Haemonetics Corporation is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Daniel Owczarski Avondale Partners Ishan Majumdar Baptista Research Gary Prestopino Barrington Research Associates, Inc.
Show 26 more analysts 
